Business

Healthcare and Business News

Updated 2026-07-29 21:10 UTC 1 source Neutral

STAT News covers Latigo Biotherapeutics' mid-stage success with a new pain drug that competes with Vertex's Journavx. This development could have significant implications for the pharmaceutical industry.

Coverage timeline — 1 article

STAT News

STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx

Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the market

2026-07-29 21:00 UTC